Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Fuji
Teva
Johnson and Johnson
Moodys
Healthtrust
McKinsey
Covington
Federal Trade Commission

Generated: October 17, 2017

DrugPatentWatch Database Preview

Elvitegravir - Generic Drug Details

« Back to Dashboard

What are the generic sources for elvitegravir and what is the scope of elvitegravir freedom to operate?

Elvitegravir
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Elvitegravir has seventy-five patent family members in thirty-three countries and fourteen supplementary protection certificates in eleven countries.

There are five drug master file entries for elvitegravir.

Summary for Generic Name: elvitegravir

US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Bulk Api Vendors: see list46
Clinical Trials: see list51
Patent Applications: see list406
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:elvitegravir at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-001Sep 24, 2014DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-001Sep 24, 2014DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-002Sep 24, 2014DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-002Sep 24, 2014DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-002Sep 24, 2014DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-001Sep 24, 2014DISCNYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-002Sep 24, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-001Sep 24, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-002Sep 24, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
Gilead Sciences Inc
VITEKTA
elvitegravir
TABLET;ORAL203093-001Sep 24, 2014DISCNYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: elvitegravir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,232,4014-oxoquinoline compound and use thereof as HIV integrase inhibitor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: elvitegravir

Country Document Number Estimated Expiration
Norway20065790► Subscribe
SloveniaEP1636190► Subscribe
MexicoPA04006553► Subscribe
Russian Federation2275361► Subscribe
Japan3754064► Subscribe
Israel162548► Subscribe
Brazil0306214► Subscribe
South Africa200610647► Subscribe
European Patent Office1636190► Subscribe
South Africa200404537► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ELVITEGRAVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1564210/01Switzerland► SubscribePRODUCT NAME: ELVITEGRAVIR; REGISTRATION NO/DATE: SWISSMEDIC 62673 18.10.2013
2013 00058Denmark► SubscribePRODUCT NAME: ELVITEGRAVIR I ENHVER FORM SOM ER OMFATTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/13/830/001-002 20130524
00624Netherlands► SubscribePRODUCT NAME: ELVITEGRAVIR IN ALLE VORMEN ZOALS; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130524
C0061France► SubscribePRODUCT NAME: ELVITEGRAVIR OU UN HYDRATE, SOLVATE, TAUTOMERE, OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CEUX-CI; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130524
0130029 00095Estonia► SubscribePRODUCT NAME: ELVITEGRAVIIR/KOBITSISTAAT/EMTRITSITABIIN/TENOFOVIIR-;REG NO/DATE: K(2013)3210 (LOPLIK) 24.05.2013
90052-7Sweden► SubscribePRODUCT NAME: ELVITEGRAVIR ELLER ETT HYDRAT, ETT SOLVAT, EN TAUTOMER, ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV; REG. NO/DATE: EU/1/13/830/001 20130524
9Finland► Subscribe
2013018Lithuania► SubscribePRODUCT NAME: ELVITEGRAVIRUM; REGISTRATION NO/DATE: EU/1/13/830/001, 2013 05 24 EU/1/13/830/002 20130524
13/052Ireland► SubscribePRODUCT NAME: ELVITEGRAVIR OR A HYDRATE, SOLVATE, TAUTOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130527
2013 00058Denmark► SubscribePRODUCT NAME: ELVITEGRAVIR ELLER ET HYDRAT, ET SOLVAT, EN TAUTOMER ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Farmers Insurance
Accenture
Chubb
Harvard Business School
Covington
Baxter
Colorcon
Merck
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot